“The launch of a product that will be entirely Russian is a very important project,” said Mikhail Tsyferov, Chairman of Petrovax Pharm Board of Directors at the launch ceremony.
He expressed confidence that the Russian-made vaccine would successfully compete with the foreignanalogues, and mentioned that such quadrivalent foreign vaccines were not used in Russia earlier.
According to the information from Petrovax Pharm, the vaccine was registered in 2018 and became Russia’s first quadrivalent influenza vaccine – it protects against two influenza A virus infection (H1N1 and H3N2) and two influenza B virus infection.
“As a member of the State Duma Committee on Health Protection, I would like to say that this is very important for all people in the Russian Federation. It is very important that certain people receive prophylaxis and do not have complications following the flu or pneumococcal infection. We hope that all regions will respond to this drug, which is necessary for public health,” said Natalia Sanina, First Deputy Chairman of the State Duma Health Committee.
During the ceremony there was also presented a new, third production line of Petrovax Pharm, which, according to the company, has invested about 1 billion rubles in the line. The new line will enable to increase the production of tablets at the enterprise seven times, the production of suppositories four times, and the production of substances 2.5 times. According to Petrovax Pharm, the launch of the third line has led to creation of 70 new jobs